Search
forLearn
5 / 801 resultslearn Beta sitsterol
learn mometasone furoate
learn Betamethasone
learn oleanolic acid
Research
5 / 750 resultsresearch Wnt Signaling Is Deranged in Asthmatic Bronchial Epithelium and Fibroblasts
Wnt signaling is disrupted in asthma, affecting cell growth and inflammation.
research Eyelash Length in Children and Adolescents with Allergic Diseases
Children and adolescents with allergies tend to have longer eyelashes.
research The Effects of Sex Hormones and some Respiratory Diseases on the Severity of Corona Virus Infection
Asthma and high testosterone increase Covid-19 severity, while progesterone protects young women.
research A REVIEW ON COLOURFUL MEHENDI: THE RISK OF PARAPHENYLENEDIAMINE
PPD in mehendi can cause serious health problems and needs regulation.
research Current options and treatment strategies for alopecia ateata in comorbidity with atopic diseases
Dupilumab and oral JAK inhibitors are effective for treating alopecia areata with atopic diseases.
Community Join
5 / 1000+ resultscommunity Cassiopea announces completion of recruitment of Phase II dose ranging trial of Breezula (CB-03-01) for androgenic alopecia
The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
community RU-58841 Lung Disease Possibility | Chest pain, "heart issues", etc
Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.
community Joining clinical study for Clascoterone (Breezula)
The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.
community EMA is re-examining Winlevi (clascoterone at lower concentration)
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
community Brief update clascoterone phase 3 - Breezula
Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.